<DOC>
	<DOC>NCT02541084</DOC>
	<brief_summary>This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.</brief_summary>
	<brief_title>Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>[Patients] Female and male outpatients diagnosed with wAMD. Patients who are accompanied by his/her caregiver(s). Patients who have been receiving antiVEGF therapy with proactive regimen for 12 months or more at the participating site. Providing informed consent for the participation in this study. [Caregivers] Providing informed consent for the participation in this study. Capable of understanding and completing the questionnaires without any help from others [Patients] Presence of a disease or a condition more disabling than wAMD in term of caregiving. Presence of intractable neurologic disease, physical handicap, mental handicap, or any condition that rendered them unable to walk independently. Intraocular surgery for other eye diseases after the start of wAMD therapy. [Caregivers] Professional carers</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Caregiver burden</keyword>
	<keyword>Anti-vascular endothelial growth factor (VEGF) therapy</keyword>
</DOC>